M5717

Merck KGaA

Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
  • Potential for prophylaxis

MoA
  • P. falciparum EF2 inhibitor novel mechanism of action

Key features
  • Comparable activity across all stages of the malaria parasite lifecycle 

  • Predicted dose to give coverage above Minimal Parasiticidal Concentration for >8 days is 500mg 

  • Excellent transmission-blocking activity in a Standard Membrane Feeding Assay

Status
  • Phase I studies completed
Next milestone
  • Initiate combination studies with partner compounds
Previously
  • Names DDD107498; DDD498, MMV121; Discovery collaboration with the University of Dundee Drug Discovery Unit
MMV Project Director
  • Dr Jörg Möhrle